
- Volume 0 0
Epilepsy Drug Treats Pain Disorder
A small-scale study of the epilepsy drug tiagabine (Gabitril) shows promise in the treatment of complex regional pain syndrome, according to an article in a recent issue of the American Journal of Pain Management. This particular disorder refers to the diffuse pain in the arms and legs following a localized injury. After animal studies suggested that tiagabine might treat pain caused by nerve damage, researchers began a study of 20 patients with complex regional pain syndrome, also known as reflex sympathetic dystrophy. Patients received either 2 or 4 mg per day of tiagabine, increasing to doses up to 12 mg. These patients had not previously taken epilepsy drugs or had not experienced effective relief of their symptoms. After taking the drug for 24 weeks, 16 of the 20 patients reported excellent or good reduction of symptoms, while the remaining 4 reported little improvement (less than 20% reduction of symptoms). The study authors agree that further placebo-controlled trials are necessary to better assess the efficacy of tiagabine.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Articles in this issue
over 20 years ago
Antibiotics, Probiotics, and Microfloraover 20 years ago
Calcium: An Essential Mineralover 20 years ago
CAN YOU READTHESE Rxs?over 20 years ago
ECKEL RECEIVES ALUMNI AWARDover 20 years ago
Cancer: Update on Biologicsover 20 years ago
Managing Chronic Pain: An Analysis of the Use of Opioidsover 20 years ago
PHARMACIST'S RIGHT TO CHOOSE?over 20 years ago
Teenage Drug Diversion—Part 2over 20 years ago
Is Altering Refills a Criminal Act?over 20 years ago
Do All SSRIs Interact the Same Way?Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.














































































































































































































